Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerNPJ breast cancer, 2021-01, Vol.7 (1), p.1-1, Article 1 [Peer Reviewed Journal]The Author(s) 2021. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 2374-4677 ;EISSN: 2374-4677 ;DOI: 10.1038/s41523-020-00208-2 ;PMID: 33397968Full text available |
|
2 |
Material Type: Article
|
Stakeholders welcome proposal on the European Health Data SpaceThe lancet oncology, 2022-12, Vol.23 (12), p.1492-1492 [Peer Reviewed Journal]2022 Elsevier Ltd ;2022. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(22)00691-X ;PMID: 36335972Full text available |
|
3 |
Material Type: Article
|
Opportunities and priorities for breast surgical researchThe lancet oncology, 2018-10, Vol.19 (10), p.e521-e533 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30511-4 ;PMID: 30303126Full text available |
|
4 |
Material Type: Article
|
The importance of patient-reported outcomes in clinical trials and strategies for future optimizationPatient related outcome measures, 2018-01, Vol.9, p.353-367 [Peer Reviewed Journal]COPYRIGHT 2018 Dove Medical Press Limited ;COPYRIGHT 2018 Dove Medical Press Limited ;2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 Mercieca-Bebber et al. This work is published and licensed by Dove Medical Press Limited 2018 ;ISSN: 1179-271X ;EISSN: 1179-271X ;DOI: 10.2147/prom.s156279 ;PMID: 30464666Full text available |
|
5 |
Material Type: Article
|
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialThe lancet oncology, 2021-08, Vol.22 (8), p.1162-1174 [Peer Reviewed Journal]2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00302-8Full text available |
|
6 |
Material Type: Article
|
Global post-mortem tissue donation programmes to accelerate cancer researchNature reviews. Cancer, 2024-05, Vol.24 (5), p.289 [Peer Reviewed Journal]EISSN: 1474-1768 ;DOI: 10.1038/s41568-024-00683-w ;PMID: 38589555Digital Resources/Online E-Resources |
|
7 |
Material Type: Article
|
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trialThe lancet oncology, 2021-07, Vol.22 (7), p.1023-1033 [Peer Reviewed Journal]2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00196-0Full text available |
|
8 |
Material Type: Article
|
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trialThe lancet oncology, 2018-10, Vol.19 (10), p.1385-1393 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30380-2 ;PMID: 30196031Full text available |
|
9 |
Material Type: Article
|
Harnessing multimodal data integration to advance precision oncologyNature reviews. Cancer, 2022-02, Vol.22 (2), p.114-126 [Peer Reviewed Journal]2021. Springer Nature Limited. ;Springer Nature Limited 2021. ;ISSN: 1474-175X ;EISSN: 1474-1768 ;DOI: 10.1038/s41568-021-00408-3 ;PMID: 34663944Full text available |
|
10 |
Material Type: Article
|
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitorsNature reviews. Drug discovery, 2018-11, Vol.17 (12), p.854-855 [Peer Reviewed Journal]Copyright Nature Publishing Group Dec 2018 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2018.210Full text available |
|
11 |
Material Type: Article
|
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020-03, Vol.21 (3), p.335-337 [Peer Reviewed Journal]2020 Elsevier Ltd ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30096-6 ;PMID: 32066541Digital Resources/Online E-Resources |
|
12 |
Material Type: Article
|
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trialThe lancet oncology, 2019-03, Vol.20 (3), p.352-360 [Peer Reviewed Journal]2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 2019 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30813-1 ;PMID: 30711522Full text available |
|
13 |
Material Type: Article
|
Translational research in neuroendocrine tumors: pitfalls and opportunitiesOncogene, 2017-04, Vol.36 (14), p.1899-1907 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Apr 6, 2017 ;Macmillan Publishers Limited, part of Springer Nature. 2017. ;ISSN: 0950-9232 ;EISSN: 1476-5594 ;DOI: 10.1038/onc.2016.316 ;PMID: 27641330 ;CODEN: ONCNESFull text available |
|
14 |
Material Type: Article
|
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trialThe lancet oncology, 2020-04, Vol.21 (4), p.508-518 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30074-7 ;PMID: 32135080Full text available |
|
15 |
Material Type: Article
|
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialThe lancet oncology, 2019-11, Vol.20 (11), p.1531-1543 [Peer Reviewed Journal]2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2019. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30569-8 ;PMID: 31540791Full text available |
|
16 |
Material Type: Article
|
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialThe lancet oncology, 2018-04, Vol.19 (4), p.497-509 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Apr 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30111-6 ;PMID: 29501363Full text available |
|
17 |
Material Type: Article
|
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsThe lancet oncology, 2020-04, Vol.21 (4), p.531-540 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30856-3 ;PMID: 32105622Full text available |
|
18 |
Material Type: Article
|
Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challengesCancer letters, 2020-02, Vol.471, p.61 [Peer Reviewed Journal]2019. Elsevier B.V. ;ISSN: 0304-3835 ;EISSN: 1872-7980 ;DOI: 10.1016/j.canlet.2019.12.007Digital Resources/Online E-Resources |
|
19 |
Material Type: Article
|
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyThe lancet oncology, 2020-10, Vol.21 (10), p.1353-1365 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30445-9 ;PMID: 32919526Full text available |
|
20 |
Material Type: Article
|
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyThe Lancet (British edition), 2021-09, Vol.398 (10306), p.1157-1169 [Peer Reviewed Journal]2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00889-8Full text available |